Redeye leaves a short comment on today’s news that Xbrane and STADA have secured EU approval for Xim...
Redeye is pleased that Bioservo’s Carbonhand 2.0 has now been classified and approved as a medical d...
Redeye provides a first comment on the back of Modelon's Q3 report.
Q3 adj. EBITA -20% vs ABGSCe due to North America Guides for recovery in Q4 and reiterates 2022 guid...
Sammantaget var kvartalet positivt med ett förväntat utfall.
Redeye comments on Alzecure’s Q3 report, which came in as expected.
Monivent har en pågående företrädesemission om cirka 14,8 MSEK och en riktad emission om cirka 1,6 M...
Redeye updates estimates and valuation in G5 following its Q3-results.
Redeye updates its estimates and base case following Freemelt’s Q3 report, which came in slightly be...
Redeye is encouraged by TH1NG announcing it has won the public procurement from Jönköping Municipali...
Redeye updates its estimates following Surgical Science’s Q3 2022 report, which we judge featured so...
Redeye comments on Cantargia's third quarter report and events after the end of the quarter, includi...
Relais' Q3 results were in line with our expectation and above the low-quality Refinitiv consensus.
With activity picking up from mid-September onwards, as expected, we are optimistic about Raketech's...
We revise our ’22e-’24e sales forecasts by 0 to +2%.
The 3rd of November, Eevia Health (“Eevia” or “the company”) announced that the company has develope...
IRLAB Therapeutics has reported Q322 results, providing an operational and financial update that are...
Redeye is surprised to see the strong recovery in gross margins in Q3.
Redeye raises its full-year 2022 forecast but maintains its previous expectations for the years afte...
Redeye comments on the events of the third quarter, including progress with the main candidate Pulmo...
